# Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research

> **NCT00250887** · PHASE2 · COMPLETED · sponsor: **University of Zurich** · enrollment: 22 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** Gefitnib

## Key facts

- **NCT ID:** NCT00250887
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2007-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250887, "Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00250887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*